MXPA06004899A - Controlled release analgesic suspensions - Google Patents

Abstract

A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, or acetaminophen via a liquid suspension is provided. This method provides improved therapeutic effect, in particular pain relief, over extended time periods.

Description

ANALGESIC SUSPENSIONS OF CONTROLLED RELEASE The present invention relates to a controlled release pharmaceutical formulation suitable for liquid dosage forms for the administration of active ingredients, such as analgesics.

BACKGROUND OF THE INVENTION Therapeutic agents to treat pain, inflammation, and fever include analgesics, anti-inflammatory drugs, and antipyretics. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a type of said therapeutic agents. They include propionic acid derivatives, acetic acid derivatives, fenamic acid derivatives, biphenylcarbodilic acid derivatives, oxicams and selective cyclooxygenase-2 (COX-2) NSAIDs. Propionic acids include, for example, ibuprofen, naproxen and ketoprofen. lbuprofen, in particular is a well-known NSAID widely used that possesses analgesic and antipyretic properties. It has been commercially available as a direct purchase drug in many forms for several years. Ibuprofen is chemically known as 2- (4-isobutylphenyl) -propionic acid. The NSAIDs are typically administered on a basis of one to four times a day, and the daily dose ranges from about 50 to about 2000 milligrams, preferably from about 100 to 1600 and particularly from about 200 to about 1200 milligrams. Acetaminophen is a known analgesic, with a daily dose ranging from about 325 to about 4000 milligrams, preferably from about 650 to about 4000 milligrams. Acetaminophen was first used in medicine by Van Merlng in 1893, but only since 1949 has it gained popularity as an effective alternative to aspirin for analgesic uses in the open market. The pharmacology of APAP is reviewed by B. Ameer et al., Ann. Int. Med. 87, 202 (1977). Considering the widespread use of APAP and the volume of its manufacture, both its use and its manufacture as an analgesic are known to those skilled in the art. It is known to administer NSAID, acetaminophen, and other drugs in multiple doses for 12 or 24 hours. For example, it is known to administer multiple doses containing equal amounts of ibuprofen for 12 to 24 hours. In addition, it is also known to administer a higher initial dose, followed by relatively low maintenance doses. See, for example, Palmisano et al., Advances in Therapy, Vol. 5, No. 4, July / August 1988 (use of multiple doses of ketoprofen (initial dose of 150 mg followed by subsequent doses of 75 mg) and buprofen (initial dose of 800 mg followed by subsequent doses of 400 mg.) In particular, with respect to orally administered analgesics, the desire to extend the duration of the therapeutic effect led to the development of controlled release formulations that allow simple daily administration. In a beneficial way, once-a-day administration improves patient compliance with recommended dosages during therapeutic treatment.Drug-release pharmaceutical dosage forms have long been used to optimize drug delivery and improve patient compliance, especially by reducing the number of doses of medicine that the patient must take in a day. It is advisable to reduce the rate of release of a drug or other active ingredient from a dosage form in the gastrointestinal fluids ("g.i.") of a patient, especially in order to provide a prolonged action of the drug in the body. The rate at which an orally delivered drug reaches its site of action in the body, depends on a number of factors, including the speed and extent of drug absorption in the blood through the mucosa g.i. However, before a drug can be absorbed into the blood, it must first be dissolved in the fluids g.i. For many drugs, absorption through membranes g.i. it is relatively fast compared to its dissolution in g.i. fluids, which converts the drug solution into the rate-limiting step in drug absorption. Therefore, a formulator can effectively control the speed of absorption of the drug in the blood by modifying the dissolution rate of the drug.

It is also particularly advisable that a pharmaceutical dosage form provides more than one drug, each at a modified rate. Because the onset and duration of the therapeutic efficacy of drugs varies widely, as well as their respective absorption, distribution, metabolism and elimination, it is often advisable to modify the release of different drugs in different ways, or that a first drug be released immediately. of the dosage form, while a second drug is released in a "modified" manner, for example, either in a delayed or controlled manner. Known mechanisms through which a dosage form can deliver a drug at a controlled rate (eg, sustained, prolonged, extended or delayed release) include diffusion, erosion and osmosis. It is often practical to design dosage forms that utilize a combination of the above mechanisms to obtain a particularly desirable controlled release profile for a particular active ingredient. Unfortunately, many controlled release applications employ solid dosage units that have a large size and final weight. The administration of such dosing units presents a problem especially for those patients with difficulty swallowing, such as children and elderly people. Therefore, it is also advisable to provide such controlled release medicines either in a chewable or orally disintegrable solid form or in a liquid form. For many patients, liquid oral dosage forms are more preferred because they can be swallowed without the additional step of chewing. Oral liquid forms have been commonly used to deliver immediate-release medications for many years. See, for example, the patents of E.U.A. Nos. 5,374,659; 4,788,220; 4,975,465; and 5,183,829. However, the incorporation of a controlled release medicament in a liquid dosage form presents important formulation challenges. In particular, coated or chemically bound particles are usually employed to carry the modified release portion of the drug. The properties of said particles, as well as those of the liquid vehicle for suspending them, must be compatible so that the particles can be maintained in a uniformly dispersed state. A particular challenge is the prevention of a premature release of drug from the suspended particles during the storage life of the liquid dosage form before ingestion by a patient. In addition, maintaining the desired dissolution profile as well as the desired dose uniformity of the liquid dosage form during its shelf life are additional challenges that will be addressed when formulating an oral controlled release liquid suspension product. In U.S. Patent No. 5,527,545, microgranules of active ingredient were coated with four consecutive coatings in order to preserve the release characteristics of the dosage form in a liquid suspension. However, the multiple coating step not only increased the overall cost and cycle time of production of the product, but also the resulting dosage forms did not provide an immediate release dose to the user. Therefore, it would also be advisable to have a controlled release, liquid dosage form having an active ingredient that can be suspended, such as an analgesic, which is not only pleasant to the palate, but also that is in a stable form that guarantee the required release profile after administration. It would also be advisable to have an analgesic suspension product that provides the user with an immediate release dose and a sustained release dose of analgesic.

BRIEF DESCRIPTION OF THE INVENTION The invention provides a pharmaceutical dosage form suitable for the administration of NSAID and / or acetaminophen in a liquid suspension, said dosage form comprises, consists of and / or consists essentially of: a) a first portion containing an NSAID and / or acetaminophen, NSAID and / or acetaminophen are released from the dosage form in a substantially immediate manner upon contact of the dosage form with a dissolution medium; and b) a second portion of particles containing NSAID and / or acetaminophen, the NSAID and / or acetaminophen are released from the particles in a controlled manner upon contact of the dosage form with the dissolution medium, wherein the pharmaceutical dosage form it has a duration of therapeutic effect for at least about 8 hours after its administration. Another embodiment of the present invention relates to a liquid suspension dosage form which comprises, consists of, and / or consists essentially of: a) a first portion containing an NSAID and / or acetaminophen, the NSAID and / or acetaminophen are released from the dosage form in a substantially immediate manner upon contact of the dosage form with a dissolution medium; b) a second portion of particles containing NSAID and / or acetaminophen, the NSAID and / or acetaminophen are released from the particles in a controlled manner upon contact of the dosage form with the dissolution medium; and c) water, or mixtures of water and a pharmaceutically acceptable water-miscible co-solvent selected from the group consisting of glycols, alcohols, and glycerol, wherein the dosage form has a duration of therapeutic effect of at least about 12 hours after administration. Another embodiment of the present invention relates to a method for administering acetaminophen and / or an NSAID in a pharmaceutical dosage form to a mammal in need thereof, said method comprising, consisting of, and / or consisting essentially of, providing a mammal the dosage form for the mammal to receive an immediate release dose of said acetaminophen and / or NSAID at the beginning of said 12 hour period, and a controlled release dose of acetaminophen and / or NSAID for a period of approximately 12 hours after of administration of the dosage form, wherein no more acetaminophen and / or NSAID is provided during said 12-hour period. Another embodiment of the present invention relates to a dosage form of liquid pharmaceutical suspension comprising, consisting of, and / or consisting essentially of: particles of an NSAID and / or acetaminophen, the particles being substantially covered with a layer of a controlled release composition, wherein the dosage form of pharmaceutical liquid suspension has a duration of therapeutic effect of at least about 8 hours after its initial administration to a mammal.

Another embodiment of the present invention relates to a pharmaceutical liquid suspension dosage form which comprises, consists of, and / or consists essentially of: a) particles containing NSAID and / or acetaminophen, the particles are substantially covered with a layer of a controlled release relapse; and b) water, or mixtures of water and a pharmaceutically acceptable water-miscible co-solvent selected from the group consisting of glycols, alcohols and glycerol, wherein the pharmaceutical dosage form has a duration of therapeutic effect of at least about 8 hours after its administration. Another embodiment of the present invention relates to a method for administering acetaminophen and / or an NSAID in a pharmaceutical dosage form of liquid suspension to a mammal in need thereof, the method comprises, consists of, and / or consists essentially of providing to a mammal said dosage form for the mammal to receive a controlled release dose of said acetaminophen and / or NSAIDs for a period of about 12 hours after administration of said dosage form, wherein no further acetaminophen and / or NSAID during that 12-hour period.

Another embodiment of the present invention relates to a pharmaceutical liquid suspension dosage form which comprises, consists of, and / or consists essentially of: a) particles containing NSAID and / or acetaminophen, the particles are substantially covered with a layer of a controlled release composition, the controlled release composition is formed, based on the total weight of the controlled release composition, of more than about 0% and less than about 90% of an insoluble film forming polymer and more than about 0% to less than about 10% of an enteric polymer; and b) water, or mixtures of water and a pharmaceutically acceptable water-miscible co-solvent selected from the group consisting of glycols, alcohols and glycerol. Wherein the pharmaceutical dosage form has a duration of therapeutic effect of at least about 12 hours after its administration.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 illustrates a graph of active ingredient released (mg) versus time (hours) for a liquid suspension dosage form containing both an immediate dose and a controlled release dose of ibuprofen; and Figure 2 illustrates a graph of a released active ingredient (mg) versus time (hours) for a liquid suspension dosage form containing only a controlled release dose of ibuprofen.

DETAILED DESCRIPTION OF THE INVENTION As used herein, the term "substantially covers" or "substantially continuous" means that the backing is generally continuous and generally covers the entire surface of the underlying core or layer, so that little or nothing of the active ingredient or underlying layer is present. exposed. As used herein, "ATDAIRD" shall mean the average therapeutic duration of an effective immediate release dose of a particular active ingredient. For example, the typical duration of action, i.e., period of therapeutic effect, of an immediate release dose of ibuprofen or ketoprofen is about 4 to about 6 hours. Therefore, the ATDAIRD for ibuprofen or ketoprofen is 5 hours. The typical duration of action of an immediate release dose of naproxen is about 8 to about 12 hours. The ATDAIRD for naproxen, therefore, is 10 hours. The therapeutic duration of action of a particular active ingredient can be easily determined from the label dosage instructions for immediate release products containing that particular active ingredient. As used herein, "modified release" will apply to the altered release or dissolution of an active ingredient in a dissolution medium, such as fluids.The active ingredient (s) that can be released in a modified manner may be contained, for example, within dosage forms, coatings, or particles, or in any portion thereof, such as, for example, particles dispersed through a liquid suspension medium. The types of modified release include: 1) controlled release; or 2) delayed release. By "controlled release", it is meant that after administration, an active ingredient is released from the dosage form in a substantially continuous, regulated manner, and the time for complete release, ie, depletion, of the active ingredient of the form of dosage is more prolonged than that associated with an immediate release dosage form thereof. The types of controlled release include prolonged, sustained, extended, and the like. By "delayed release", it is meant that after administration, there is at least one period when an active ingredient is not being released from the dosage form. As used in this"means of dissolution" will mean any suitable liquid environment in which the suspension dosage form of the present invention can be dissolved, such as, for example, in vitro dissolution media used for product testing, or gastrointestinal fluids. Suitable in vitro dissolution media used to test the dissolution of the active ingredient or ingredients from the suspension dosage form of the present invention, include those described on page 786 of USP 23 (1995), which is incorporated to the present as a reference. One embodiment of the present invention relates to a controlled release pharmaceutical dosage form suitable for the administration of active ingredients in a liquid suspension containing: a) an immediate release portion, eg, a portion containing at least one ingredient active that is immediately released from the dosage form; and b) a controlled release portion, for example, a portion containing at least one active ingredient that is released into the bloodstream in a substantially continuous manner over a controlled period such as, for example, from about 4 hours to about 12 hours after of the initial administration of the dosage form. As used herein, "immediate release" means that the dissolution characteristics of at least one active ingredient meets USP specifications for immediate release tablets containing that active ingredient. For example, for acetaminophen tablets, USP 24 specifies that in phosphate pH regulator pH 5.8, using the USP apparatus 2 (blades) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released from it. 30 minutes after dosing, and for ibuprofen tablets, USP 24 specifies that in pH 7.2 phosphate buffer, using USP apparatus 2 (blades) at 50 rpm, at least 80% of the ibuprofen contained in the dosage form it is released 60 minutes after dosing. See USP 24, 2000 Version, 19-20 and 856 (1999). In addition, the ibuprofen suspension can be analyzed for dissolution using acetate pH regulator, pH 5.6 using USP apparatus 2 (blades) at 50 rpm, where at least 80% of the buprofen contained in the dosage form is released therefrom. 60 minutes after dosing for an immediate release dose. The immediate release portion may contain one or more active ingredients that are dispersed at the molecular level, eg, molten or dissolved, within the dosage form, or the active ingredient may be in the form of particles, which in turn may be be coated or uncoated In embodiments wherein the active ingredient is in the form of particles, the particles (either coated or uncoated) usually have an average particle size of about 1 miter to about 2000 microns. In one embodiment, said particles are in the form of crystals having an average particle size of about 1 miera to about 300 micras. In another embodiment, the particles are in the form of pellets or pellets having an average particle size of from about 25 microns to about 2000 microns, for example, from about 25 microns to about 1000 microns or from about 25 microns to about 400 microns. The controlled release portion contains at least one active ingredient in a multiplicity of particles having controlled release properties. In one embodiment, the core of these particles in the controlled release portion can be formed by the active ingredient in a pure, crystalline form, which is substantially coated with a controlled release composition. Alternatively, the particle cores may be formed by a mixture of granules formed by one or more active ingredients with optional ingredients, such as binders, excipients and the like known in the art, and said granules are also substantially coated with a composition of controlled release. In another embodiment, the particles of active ingredient may be dispersed through a matrix formed by a controlled release composition. Even in another embodiment, one or more active ingredients may be chemically bound or "complexed" to a resin, for example, an ion exchange resin, to form particles, which may optionally be substantially coated with a coating of controlled release. As used herein, "substantially coated" will mean that less than about 1%, for example less than about 0.1% of the surface area of the particle is exposed., for example, not covered, with a desired coating. One skilled in the art will readily appreciate without undue experimentation that the particular ion exchange resin for use in this embodiment depends on several factors, such as, for example, the ionic charge of the active ingredient. An example of a suitable ion exchange resin for active ingredients of NSAIDs includes, but is not limited to cholestyramine, which is commercially available from Rohm & amp; amp; amp; amp;; Haas under the trade name "Duolite® AP143". Further details of the complex formation with polymeric resins are known in the art and are described for example in the patents of E.U.A. Nos. 4,221,778; 4,847,077 and 6,001, 392, which are incorporated herein by reference. In a particular embodiment, the controlled release portion of the dosage form is substantially free of ion exchange resins. By "substantially free of ion exchange resins", it is meant that the amount of ion exchange resin, based on the total weight of all the particles of active ingredient in the dosage form, is less than about 1%, by example, less than about 0.05% or less than about 0.1%. The coating layer or layers in the particles can be formed by any suitable controlled release composition.

An example of a suitable controlled release composition is formed, based on the total weight of the controlled release composition, from about more than about 0% to about 90%, for example from about 10% to about 60%, of a film-forming polymer insoluble and more than about 0% to less about 10%, for example, from about 0.5% to about 20% of an enteric polymer. The weight ratio of enteric polymer to insoluble film-forming polymer in the controlled release composition may be in the range of about 0.5: 99.5 to about 20:80, eg, from about 5:95 to about 10:90. Similar controlled release compositions can also be used in the matrix through which the active ingredient particles can be dispersed. Suitable insoluble film-forming polymers include, but are not limited to cellulose acetate, ethyl cellulose, poly (ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride), 1: 2: 0.1, which is commercially available from Rohm Pharma under the trade name "EUDRAGIT RS", and copolymers and mixtures thereof. In one embodiment, the insoluble film-forming polymer is selected from cellulose acetate and / or ethyl cellulose. Suitable enteric polymers include, but are not limited to, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, polyvinyl acetate phthalate, polymethacrylate-based polymers, and copolymers and mixtures thereof. Examples of suitable polymethacrylate-based polymers include, but are not limited to poly (methacrylic acid, methyl methacrylate) 1: 2, which is commercially available from Rohm Pharma GmbH under the trade name of polymers "EUDRAGIT S" , and poly (methacrylic acid, methyl methacrylate) 1: 1, which is commercially available from Rohm Pharma GmbH under the trade name of "EUDRAGIT L" polymers. In one embodiment, the enteric polymer is selected from non-acrylate compounds, such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, polyvinyl acetate phthalate, and copolymers and mixtures thereof. In one embodiment, the controlled release composition is substantially free of enteric polymers, i.e., for example, the controlled release composition confers, based on the total weight of the controlled release composition, less than about 1% or less of approximately 0.25% enteric polymers. The active ingredient particles coated with a controlled release composition confer, based on the total dry weight of said backflushed particles, from about 5% to about 40%, for example from about 10% to about 30% of the release composition. controlled in the form of at least one coating layer.

The coated active ingredient particles can be formed by any suitable method known in the art. Suitable particle formation and coating methods include high shear granulation, fluid bed granulation, eg, rotor granulation, fluid bed coating, coacervation, spray drying, spray-freezing, and the like and are described for example in Pharmaceutical Dosage Forms: Tablets, Volume 3, edited by Herbert A. Lieberman and Leon Lachman, Chapters 2, 3 and 4 (1982). In one embodiment, the average diameter of the backfired particles with a controlled release composition is from about 20 to about 400 microns, for example, from about 50 microns to about 300 microns. The dosage form of the present invention contains one or more active ingredients. Suitable active ingredients broadly include, for example, pharmaceuticals, minerals, vitamins and other nutraceuticals, oral care agents, flavorings and mixtures thereof. Suitable pharmacists include analgesics, anti-inflammatory agents, antiarthritics, anesthetics, antihistamines, antitussives, antibiotics, anti-infective agents, antivirals, anticoagulants, antidepressants, antidiabetic agents, antiemetics, antiflatulences, antifungals, antispasmodics, appetite suppressants, bronchodilators, cardiovascular agents, agents for the central nervous system, stimulants for the central nervous system, decongestants, oral contraceptives, diuretics, expectorants, gastrointestinal agents, preparations for migraine, products for motion sickness, mucolytics, muscle relaxants, preparations for osteoporosis, polydimethylsiloxanes, respiratory agents, auxiliaries for sleep, agents for the urinary tract and mixtures thereof. Suitable flavors include menthol, mint, peppermint flavors, fruit flavors, chocolate, vanilla, chewing gum flavors, coffee flavors, liqueur flavors and combinations, and the like. Examples of suitable gastrointestinal agents include antacids, such as calcium carbonates, magnesium hydroxide, magnesium oxide, magnesium carbonate, aluminum hydroxide, sodium bicarbonate, sodium dihydroxy aluminum carbonate, stimulant laxatives, such as bisacodyl, cascara sagrada, dantrón , sena, phenoftalein, aloe, castor oil, ricinoleic acid, and dehydrocholic acid, and mixtures thereof; H2 receptor antagonists, such as famotadine, ranitidine, cimetadine, nizatidine; proton pump inhibitors such as omeprazole or lansoprazole; gastrointestinal cytoprotectants, such as sucraflate and misoprostol; gastrointestinal proclnetics, such as prucalopride, antibiotics for H. pylori, such as clarithromycin, amoxicillin, tetracycline, and metronidazole; antidiarrheals, such as diphenoxylate and loperamide; glycopyrrolate; antiemetics, such as ondansetron; analgesics, such as mesalamine.

Examples of suitable polydimethylsiloxanes, which include but are not limited to dimethicone and symmetry, are those described in the U.S. Patents. Nos. 4,906,478, 5,275,822, and 6,103,260, the contents of which are expressly incorporated herein by reference. As used herein, the term "simethicone" refers to the broader class of polydimethylsiloxanes, which include but are not limited to simethicone and dimethicone. In one embodiment of the invention, at least one active ingredient can be selected from bisacodyl, famotadine, ranitidine, cimetidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, antacids, and salts, esters, isomers and mixtures thereof. pharmaceutically acceptable In another embodiment, at least one active ingredient is selected from analgesics, anti-inflammatories and antipyretics, for example, nonsteroidal anti-inflammatory drugs (NSAIDs), which include a) propionic acid derivatives, eg, ibuprofen, naproxen, ketoprofen and the like, b) acetic acid derivatives, for example ndometacin, diclofenac, sulindac, tolmethyl, and the like; c) phenamic acid derivatives, for example mefenamic acid, meclofenamic acid, flufenamic acid, and the like; d) biphenylcarbodilic acid derivatives, for example diflunisal, flufenisal, and the like; e) oxicams, for example piroxicam, sudoxicam, isoxicam, meloxicam, and the like; f) Selective NSAIDs of cyclooxygenase-2 (COX-2); and g) salts of the above pharmaceutically acceptable.

In a particular embodiment, at least one active ingredient is selected from NSAIDs derived from propionic acid, which are analgesics / pharmaceutically acceptable non-steroidal anti-inflammatory drugs having a free group -CH (CH3) COOH or -CH2CH2COOH or a group of salts pharmaceutically acceptable, such as -CH (CH3) COO-Na + or CH2CH2COO-Na +, which are usually fixed directly or through a carbonyl functionality to a ring system, preferably an aromatic ring system. Examples of useful propionic acid derivatives include ibuprofen, naproxen, benoxaprofen, naproxen sodium, fenbufen, flurbiprofen, fenoprofen, fenbuprofen, ketoprofen, indoprofen, pirprofen, carpofen, oxaprofen, pranoprofen, microprofen, thioxaprofen, suprofen, alminoprofen, triaprofenic acid, fluprofen, bucilloxic acid, and pharmaceutically acceptable salts, derivatives and combinations thereof. In one embodiment of the invention, the propionic acid derivative is selected from buprofen, ketoprofen, flublprofen, and pharmaceutically acceptable salts and combinations thereof. In another embodiment, the propionic acid derivative is ibuprofen, 2- (4-isobutylphenyl) propionic acid, or a pharmaceutically acceptable salt thereof, such as the arginine, lysine, or ibuprofen histidine salt. Other pharmaceutically acceptable salts of buprofen are described in the U.S. Patents. Nos. 4,279,926, 4,873,231, 5,424,075 and 5,510,385, the contents of which are incorporated by reference.

In another particular embodiment of the invention, at least one active ingredient can be selected from acetaminophen, acetylsalicylic acid, ibuprofen, naproxen, ketoprofen, flurbiprofen, diclofenac, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and salts, esters, isomers and mixtures pharmaceutically acceptable thereof. In another particular embodiment of the invention, at least one active ingredient can be selected from pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, astemizole, terfenadine, fexofenadine, loratadine, desloratadine, cetirizine, mixtures thereof and salts, esters, isomers and pharmaceutically acceptable mixtures thereof. In another particular embodiment, at least one active ingredient is an NSAID and / or acetaminophen, and pharmaceutically acceptable salts thereof. In one embodiment, a therapeutically effective amount of the active ingredient or ingredients may be present in a "unit dose volume" which may be in the form of a powder or an aqueous suspension. "Therapeutically effective amount", as used herein, is an amount of active ingredient that produces the desired therapeutic response after oral administration. One skilled in the art can easily determine the "therapeutically effective amount" of an active ingredient for a given patient when considering factors such as for example the particular active ingredient that is administered; the bioavailability characteristics of the active ingredient; the desired dosage regimen; the age and weight of the patient; and similar. As used herein, a "unit dose volume" can be any convenient volume to orally deliver a dose of a particular product to a patient. In this embodiment, the "unit dose volume" is typically accompanied by dosage instructions, which indicate the patient to take an amount of the active ingredient that can be a multiple of the unit dose volume depending, for example, on age or weight of the patient. Usually, the unit dose volume of the suspension will have a quantity of active ingredient that is therapeutically effective for the smaller patient. For example, suitable unit dose volumes may include one teaspoon (approximately 5 mL), one teaspoon (approximately 15 mL), one dropper, or one milliliter. According to the invention, a dosage form containing NSAID and / or acetaminophen can be provided to a mammal in need of treatment, in particular pain relief treatment in a single administration that provides for the release of the active ingredient in the blood. during an extended period, for example, during approximately a period of 8 hours or approximately a period of 12 hours. At time zero, an initial dose of NSAID and / or acetaminophen is administered to the mammal through the active ingredients in the immediate release dose portion. The active ingredient continues to be released into the blood after about four, for example, that is, about eight, ten, or twelve hours from the initial administration of the formulation containing the active ingredient through the active ingredients in the portion of controlled release dose. In other words, the formulation still retains undissolved active ingredient after about four, e.g., about eight, ten or twelve hours from the initial administration. To practice the present invention, the dosage form can be formed, based on the total weight of the active ingredient, from about 25% to about 75% of an immediate release dose portion of the active ingredient; and from about 75% to about 25% of a controlled release dose portion of the active ingredient. The immediate release dose portion and the controlled release dose portion can be combined with a carrier to form either a dry mixture that can be suspended extemporaneously when necessary, or a liquid suspension ready for use. Suitable constituents of the vehicle may include, without limion, structuring agents; dilaon agents; surfactants; sugars; pH regulating substances such as citric acid and sodium citrate; glycine and hydrochloric acid, sodium phosphate, and potassium phosphate; preservatives and bacteriosc agents such as p-hydroxybenzoic acid esters, dyes; and various flavors and sweeteners commonly used in pharmaceuticals. Examples of suitable sweeteners include, but are not limited to, any known sweetening agents such as sugars, sugar alcohols, high intensity sweeteners, and mixtures thereof. Suitable sugars include, but are not limited to, sucrose, dextrose, high fructose corn syrup, and maltose. Suitable sugar alcohols include, but are not limited to sorbitol, xylitol and mannitol. Suitable high intensity sweeteners include, but are not limited to sucralose, aspartame, saccharin, and acesulfame K. In one embodiment, an effective amount of a pH regulating agent is used in order that the pka of at least one Active ingredient contained in the controlled release portion of the liquid suspension dosage form is greater than the pH of the entire liquid suspension dosage form. further, the vehicle can also be made up of water or mixtures of water and a pharmaceutically acceptable water-miscible co-solvent known in the art, such as for example, alcohols, glycerol and alcohols. In some embodiments, the dosage form may include any suspension system known in the art, such as those that usually include one or more structuring agents and / or one or more dilatation agents. In one embodiment, the dosage form contains, based on the total weight of the liquid suspension dosage form, from about 0.1% to about 10% of a suspension system. Suitable suspension systems include those described for example in U.S. Patent Nos. 5,374,659, 5,621, 005, and 5,409,907, which are hereby incorporated by reference in their entirety. Structurants that are suitable for use in the present invention include hydrophilic polymers such as hydrocolloids. Examples of suitable hydrocolloids include alginates, agar, guar gum, locust bean, carrageenan, tara, gum arabic, tragacanth, pectin, xanthan, gelano, maltodextrin, galactomannan, pustulana, laminarin, scleroglucan, gum arabic, inulin, karaya, welan, rhamsan , zooglan, methylan, chitin, cyclodextrin, chitosan and combinations thereof. In certain embodiments of the present invention, xanthan gum is the structuring agent. Xanthan gum is a natural carbohydrate of high molecular weight, specifically, a polysaccharide. A xanthan gum which is suitable for use in the present invention is a high molecular weight polysaccharide produced by Xanthomonas campestris. Techniques and strains for producing this polysaccharide are described in the US Pat. Nos. 4,752,580 and 3,485,719, the disclosures of which are incorporated herein by reference. In one embodiment, the xanthan gum can have a viscosity in a 1% saline solution of about 1000 to about 1700 cP (mPa-sec), measured at 25 ° C with a Brookfield Synchro-Lectric viscometer model LV at 60 rpm, spindle number 3. Suitable xanthan gums are available, for example from CP Kelco, under the tradename "Keltrol," "Keltrol TF," and "Keltrol 1000." A dilation agent, when exposed to a suitable aqueous environment, expands without forming a network system. Pregelatinized starch is a particularly good dilation agent. The pregelatinized starch, also known as "instantized" starch, is precooked so that it dilate and start to thicken instantaneously when added to cold water. A particularly suitable pregelafinized starch is prepared from modified, stabilized and waxy food-grade corn starch and is commercially available from the National Starch Company as "INSTANT STARCH, ULTRASPERSE-M". Other suitable dilation agents include, but are not limited to, microcrystalline cellulose and / or hydroxypropyl cellulose. In one embodiment, the suspension system is comprised of a structuring agent of xanthan gum with a pregelatinized starch dilation agent. In another embodiment, the suspension system is formed based on the total weight of the liquid suspension dosage form, from about 0.01% to about 1% or from about 0.05% to about 0.40% xanthan gum and about 1 % to about 10% or from about 0.5% to about 3.0% of a pregelatinized starch such as is commercially available from the National Starch Company under the trade name "INSTANT STARCH, ULTRASPERSE-M". In one embodiment, the dosage form is in the form of an aqueous pharmaceutical suspension composition and is formed, based on the total weight of the active ingredient per volume (w / vg / 100ml) of the aqueous pharmaceutical suspension of more than about 0. % to approximately 40%, for example about 0.05% to about 0.2%, or about 1.6% to about 10%, or about 15% to about 40% of at least one active ingredient. In an embodiment wherein the active ingredient is loraidin, the amount of active ingredient in the suspension dosage form, based on the total weight of active ingredient per volume (w / v) of the suspension dosage form accuses, is from about 0.05% to about 0.2%, which is equivalent to about 2.5 milligrams to about 10 milligrams of loratidine per teaspoon of aqueous suspension dosage form. In another embodiment wherein the active ingredient is acetaminophen, the amount of active ingredient in the suspension dosage form, based on the total weight in the active ingredient per volume (w / v) of the aqueous suspension dosage form, it is from about 1.6% to about 3.2%, which is equivalent to about 80 mg to about 160 mg per teaspoon of dosage form of suspension accuses. Even in another embodiment containing acetaminophen, the amount of active ingredient in the suspension dosage form based on the total weight of active ingredient per volume (w / v) of the aqueous suspension dosage form is approximately 5%. to about 10%, which is equivalent to about 80 mg to about 160 mg per 1.6 mL of aqueous suspension dosage form. In another embodiment, wherein the active ingredient is ibuprofen, the amount of active ingredient in the suspension dosage form, based on the total weight of the active ingredient per volume (w / v) of the aqueous suspension dosage form, is from about 50 to about 200 mg, for example from about 50 mg to about 100 mg per teaspoon of aqueous dosage form, or is from about 40 mg of active ingredient per 1 mL of aqueous suspension dosage form, which is equivalent, based on the total weight of the active ingredient per volume (w / v) of the aqueous suspension dosage form, from about 1% to about 4%. One embodiment of the present invention relates to a liquid measurable suspension composition which includes, based on the total weight of the suspension: a) from about 0.05% to about 40% of at least one active ingredient; b) from about 20% to about 70% water; c) from about 0.1% to about 10% of a suspension system; d) from about 0% to about 40%, for example, from about 20% to about 40% of a sweetening agent; and e) from about 0% to about 0.2% excipients. In that embodiment, based on the photoactive weight of the active ingredient, from about 50% to about 75% of the active ingredient is in the immediate release dose portion and from about 25% to about 50% of the active ingredient is in the serving portion. of controlled release dose. In this same embodiment, based on the total weight of the liquid suspension, from about 0.025% to about 30% of the dosage form is comprised of active ingredient in the immediate release dose portion and from about 0.0125% to about 0.025 % of that dosage form is comprised of active ingredient in the controlled release dose portion. In certain embodiments, the viscosity of the suspension of the present invention may vary from about 400 cps to about 1500 cps as measured by a Brookfield DV-I + viscometer using a number 31 spindle and speed of 12 rpm under temperature conditions of about 25 °. C. Another embodiment of the present invention relates to an aqueous suspension dosage form that confers active ingredient particles that are substantially coated or coated with a controlled release coating layer, and / or contain particles of active ingredient that are dispersed in a matrix formed by the controlled release composition. The dosage forms of the present invention are intended to deliver an effective amount of active ingredient, such as an NSAID and / or acetaminophen, into administrations once or twice a day. An "effective amount" of pain reliever is one that provides pain relief in a patient. For example, a typical adult dose of ibuprofen may vary from about 2.9 to about 12 mg / kg of patient weight given every 4 to 6 hours, for a typical daily dose ranging from about 11.6 to about 72 mg / kg / day . Therefore, administration of an effective amount of buprofen to a typical 70 kg adult may involve once or twice a day administration of about 5 ml to about 60 ml of the formulation of the present invention containing, for example , 40 mg / ml of buprofen. A typical pediatric dose of ibuprofen can range from about 5 to about 10 mg / kg given every 4 to 6 hours, for a typical daily dose ranging from about 20 to about 60 mg / kg / day. The administration of an effective ibuprofen to a typical 15 kg child may involve once or twice a day administration of about 5 ml to about 30 ml of the formulation of the present invention containing, for example, 20 mg / ml of buprofen. Oral administration of the dosage forms of the present invention provides the user with the active ingredients, such as NSAID and acetaminophen in an optional immediate release dose as well as in a controlled release dose which continues to release the active ingredient from the dosage form after about 6 hours, for example, after about 8 hours or after about 10 hours from the administration. In a beneficial manner, it has unexpectedly been found how to effectively stabilize the release characteristics of the controlled release portion of the dosage form through the shelf life of the product and throughout the treatment period, regardless of whether the Dosage is designed as a liquid dosage form, such as a suspension, or as a dry dosage form that can be reconstituted with water prior to administration. Specifically, the challenge of avoiding the release of active ingredient from the particles in the product before ingestion has been overcome, while allowing the controlled release of active ingredient from these same particles in the g.i. Advantageously, the formulations of the present invention can be used in a variety of formats including, for example, (i) dry formulations or precisely measurable single dose liquid suspensions.; (ii) granulated multi-dose formulations having an important dose flexibility that can be obtained by measuring different amounts of granules that will be resuspended as needed; (iii) liquid suspensions of multiple doses; and (iv) concentrated drops in which the active ingredient is suspended, which is particularly useful in pediatric applications. In addition, because the formulation is convenient to administer and swallow, and that the number of daily doses of the active ingredient is reduced, general compliance of the patient is achieved. Additional benefits are anticipated in pediatric practice due to the ease of swallowing and administration. Unlike the controlled release pharmaceutical suspensions of the prior art, which require a series of enteric coatings to be applied to the pharmaceutical active agent in order to produce a stable suspension on the shelf, the suspended pharmaceutical particles of the present invention need only to be coated with a layer of the novel sustained release coating in order to obtain stability in the presence of water or other water-miscible co-solvents. The following examples further illustrate the invention, but are not intended to limit the same in any way.

EXAMPLE 1 Preparation of controlled release coating solution A coating solution was prepared by dispersing methacrylate copolymer, which is commercially available from Rohm Pharma, Inc. under the trade name "Eudragit L-100", and cellulose acetate in a solvent that contains, based on the total weight of the solvent, 98% acetone and 2% water under ambient conditions. The resulting coating solution contained, based on the total wet coating solution, 7.6% cellulose acetate, 0.4% methacrylate copolymer, 90.2% acetone and 1.8% water. The relative amounts of solids were, based on the total weight percentage of the dry coating solution, 95.00% cellulose acetate and 5.00% methacrylate copolymer.

EXAMPLE 2 Preparation of coated active ingredient Preparation of ibuprofen premix The USP ibuprofen powder was combined with colloidal silicon dioxide to form the following premix of ibuprofen: Component Percent by weight * Colloidal silicon dioxide 2.00% lbuprofen USP 98.00% * Based on the total weight of the ibuprofen premix Preparation of coated ibuprofen granules: The above-prepared ibuprofen mixture was subsequently coated with the wet controlled release coating solution prepared according to Example 1 at a rate of about 20.0 g / min in a Glatt GPCCG-5/9 Wurster fluid bed coating unit under Product temperature conditions of approximately 29-32 ° C. The resulting coated ibuprofen granules contained, based on the total dry weight of the buprofen granules and the controlled release coating, about 20% of the controlled release coating.

EXAMPLE 3 Production of suspension base containing immediate release dose and controlled release dose Preparing the suspension base TABLE A Suspension base components As indicated above in Table A, purified USP water was charged to a mixing tank equipped with a Scout Turbon high shear mixer and mixed at approximately 500 rpm at approximately 1000 rpm in order to create a good swirling effect . The pregelatinized starch and the xanthan gum were subsequently added to the mixing tank and mixed for 20 minutes. Subsequently, the glycerin was added thereto and mixed for 5 minutes. The sucrose was then added and mixed for 10 minutes. Subsequently, the polylsorbate-80 NF, citric acid USP and sodium benzoate NF were added, and then the resulting mixture was mixed for 10 minutes. Subsequently, the remainder of the purified water was added with mixing to form the suspension base.

Preparation of suspension with active ingredient: After 2000.0 mg of USP ibuprofen were sieved through a 50 mesh screen, 25.0 mL of the base was added. previously prepared suspension with mixing until the mixture was homogeneous. 1276 mg of controlled release coated ibuprofen prepared according to example 2 (which contained 78.4% active ibuprofen) was subsequently sieved between 60 and 80 mesh sieves and subsequently added to the mixture.

The resulting suspension was subsequently diluted in a volume of 100.0 mL with the additional suspension base and mixed until the resulting suspension was homogeneous. After sieving the resulting suspension through a 40 mesh screen, the suspension The final final sieve contained 100 mg / 5 mL of the immediate release ibuprofen dose and 50 mg / mL of the controlled release ibuprofen dose. The relative amounts of ibuprofen particles were, based on the total dose of the final sieved suspension: Ibuprofen USP (Immediate release dose) 100.0 mg / 5 mL Coated Ibuprofen (Controlled release dose) ... 50.0 mg / 5 mL EXAMPLE 4 Analysis of suspension base solution containing immediate release dose and controlled release dose 900 mL of acetate pH regulator dissolution means pH 5.6 were placed in each of the three containers of a USP type II apparatus with blades. Subsequently, a 5.0 mL sample of the final suspension produced in Example 3 was added independently to each of the three containers and mixed at a rate of 50 rpm at 37 ° C until the mixture was homogeneous. Then, after 0.5, 1, 2, 3, 4, 6, 8, and 12 hours, respectively, samples of 10 ml of the suspension / buffer mixture were independently removed from the containers. Each 10 ml sample was subsequently analyzed independently for ibuprofen content using a high pressure liquid chromatograph (HPLC) equipped with a Waters® 717 autoinjector and a Waters® 486 UV detector set at a wavelength of 254 nm with the In order to derive the dissolution curves for ibuprofen at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours, respectively. Each of the samples was compared with a standard buprofen sample containing dissolution media of 0.167 mg buprofen / mL acetate pH buffer (pH 5.6), which correlated with the theoretical concentration required for 100% of ibuprofen release. The mobile phase used in HPLC was prepared by using a sample containing 55% acetonitrile and 45% pH buffer of 18 mM potassium phosphate. The injection volume was 200 μL with an operating time of approximately 7 minutes and a pump flow of 1.5 mL / min. The column used for analysis was a Phenomenex LUNA® 5um C8 (4.6 mm x 15 cm). The results of this dissolution analysis are set forth in Figure 1, which indicates that the suspension of the present invention may contain both an immediate release dose of an active ingredient as well as a controlled release dose of an active ingredient, thereby which the controlled release dose released ibuprofen for a period of approximately 12 hours from the initial administration.

EXAMPLE 5 Production of suspension base containing controlled release dose The procedure of Example 3 was repeated, but without the addition of the 2000.0 mg of USP ibuprofen. The resulting final sieved suspension contained 100mg / 5mL of the dose of controlled release buprofen.

EXAMPLE 6 Dissolution analysis of the suspension base containing controlled release dose The procedure of Example 4 was repeated, but with samples of the final suspension produced in Example 5. The results of the solution analysis are set forth in Figure 2, which indicates that the suspension of the present invention may contain a release dose. Controlled of an active ingredient in the substantial absence of an immediate release dose of an active ingredient, whereby the release dose conirroded ibuprofen was released over a period of approximately 12 hours from the initial administration.

Claims (22)

NOVELTY OF THE INVENTION CLAIMS

1. - A dosage form of pharmaceutical liquid suspension comprising: particles of an NSAID and / or acetaminophen, said particles being substantially covered with a layer of a conjugated release composition, wherein the pharmaceutical liquid suspension dosage form has a duration of therapeutic effect for at least about 8 hours after its initial administration to a mammal.

2. The dosage form according to claim 1, further characterized in that it additionally comprises a vehicle for the administration of the particles.

3. The dosage form according to claim 2, further characterized in that the vehicle comprises one or more agents selected from the group consisting of suspension systems, surfactants, sweeteners, pH regulating agents, preservatives, flavoring agents, and mixtures thereof.

4. The dosage form according to claim 2, further characterized in that the carrier comprises water or mixtures of water and a pharmaceutically acceptable water-miscible co-solvent selected from the group consisting of glycols, alcohols and glycerol.

5. - The dosage form according to claim 1, further characterized in that said particles are formed by a core that is substantially covered by the controlled release composition.

6.- The dosage form in accordance with the claim 5, further characterized in that said controlled release composition is formed, based on the total dry weight of the coating, of more than about 0% and less than about 100% of an insoluble film forming polymer and from 0% to less than about 10% of an enteric polymer.

7. The dosage form according to claim 5, further characterized in that said controlled release coating is substantially free of enteric polymers, and the pKa of at least one active ingredient contained in the particles is greater than the pH of the form Dosage of liquid suspension.

8. The dosage form according to claim 5, further characterized in that the weight ratio of the insoluble film-forming polymer and the enteric polymer in the controlled release coating is from about 80:20 to about 99: 1.

9.- The dosage form in accordance with the claim 5, further characterized in that the insoluble film-forming polymer is selected from the group consisting of cellulose acetate, ethylcellulose, poly (ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) in a weight ratio of 1: 2: 0.1 , and mixtures thereof.

10. The dosage form according to claim 5, further characterized in that the enteric polymer is selected from the group consisting of hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, polyvinylacetate phthalate, polymethacrylate-based polymers , and copolymers and mixtures thereof.

11. The dosage form according to claim 10, further characterized in that the polymer based on polymethacrylate is poly (methacrylic acid, methyl methacrylate) in a weight ratio of 1: 2 and / or poly (methacrylic acid, methyl methacrylate) in a weight ratio of 1: 1.

12. The dosage form according to claim 5, further characterized in that the coated particles are formed, based on the total dry weight of the backfill particles, from about 10% to about 40% of the controlled release composition.

13. The dosage form according to claim 1, further characterized in that said therapeutic effect is pain relief.

14. - The dosage form according to claim 1, further characterized in that the NSAID is an NSAID derived from propionic acid.

15. The use of a dosage form of claim 1, for preparing a medicament for treating pain in a mammal for a period of at least about 12 hours after its administration.

16. A dosage form of pharmaceutical liquid suspension comprising: a) particles containing NSAID and / or acetaminophen, said particles are substantially covered with a layer of a controlled release coating; and b) water or mixtures of water and a pharmaceutically acceptable water-miscible co-solvent selected from the group consisting of glycols, alcohols and glycerol, wherein the pharmaceuic dosage form has a duration of therapeutic effect for at least about 8 hours after of administration.

17. The pharmaceutical liquid suspension according to claim 16, further characterized in that it comprises, based on the total weight of the liquid suspension: a) from about 0.05% to about 40% of particles containing NSAID and / or acetaminophen, said particles are substantially covered with a layer of a controlled release coating; and b) from about 20% to about 70% water, or mixtures of water and a pharmaceutically acceptable water miscible co-solvent selected from the group consisting of glycols, alcohols and glycerol, wherein the dosage form has a duration of effect therapeutic for at least about 8 hours after administration.

18. The use of a dosage form of claim 17, for preparing a medicament for treating pain in a mammal for a period of at least about 12 hours after its administration.

19. The use of acetaminophen and / or an NSAID to prepare a pharmaceutical dosage form of liquid suspension with a controlled release dose of said acetaminophen and / or NSAID for a period of about 12 hours after administration of said dosage form , where no more acetaminophen and / or NSAIDs are provided during that 12-hour period.

20. A dosage form of pharmaceutical liquid suspension comprising: a) particles containing NSAID and / or acetaminophen, said particles are substantially covered with a layer of a controlled release composition, said controlled release composition is formed, with base in the total weight of the controlled release composition of more than about 0% and less than about 90% of an insoluble film forming polymer and more than about 0% to less than about 10% of an enteric polymer; and b) water or mixtures of water and a pharmaceutically acceptable water-miscible co-solvent selected from the group consisting of glycols, alcohols and glycerol, wherein the pharmaceutical dosage form has a duration of therapeutic effect for at least about 12 hours after of his administration.

21. The dosage form of pharmaceutical liquid suspension according to claim 20, further characterized in that it additionally comprises, based on the total weight of the dosage form: a) from about 0.05% to about 40% of particles containing NSAID and / or acetaminophen, said particles are substantially covered with a layer of a controlled release composition, said controlled release composition being formed, based on the total weight of the controlled release composition, of more than about 0% and less about 90% of a nonsoluble film-forming polymer and more than about 0% to less than about 10% of an enteric polymer; and b) from about 20% to about 70% water, or mixtures of water and a pharmaceutically acceptable water miscible co-solvent selected from the group consisting of alcohols, alcohols and glycerol, wherein the dosage form has a duration of effect therapeutic for at least about 12 hours after administration.

22. The dosage form according to claim 21, further characterized in that the weight ratio of the insoluble film-forming polymer and the enteric polymer in the controlled release coating is from about 99: 1 to about 80:20.